MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF), a biotechnology innovator commercializing AI-powered voice analytics for real-time drug and alcohol impairment detection, is moving toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with a focus on industrial safety applications in South America's mining sector.
The company recently appointed Chilean drug policy specialist Felipe Leyton to lead commercialization efforts in the region, a move that signals MindBio's transition from development to market entry. MindBio's technology analyzes voice patterns to detect intoxication or impairment without biological testing, positioning the platform as a scalable tool for workplace safety in mining and other high-risk industries.
The company is preparing to deploy its platform in industrial environments beginning in 2026, with Chile's mining sector, employing more than 200,000 workers, representing an early target market. The mining industry, particularly in South America, faces significant safety challenges related to impairment from drugs and alcohol, which can lead to accidents and fatalities. Traditional testing methods, such as breathalyzers or saliva tests, are often invasive, time-consuming, and require specialized equipment or personnel. MindBio's voice-based detection offers a non-invasive, rapid alternative that could be integrated into routine safety checks or access control systems.
The company also recently closed an upsized non-brokered private placement of up to $1.5 million to support commercialization activities. This funding will likely be used to finalize the platform's development, conduct pilot programs in mining operations, and scale the technology for broader industrial use.
The appointment of Felipe Leyton underscores the strategic importance of the South American market. Leyton's expertise in drug policy and his experience in the region are expected to facilitate partnerships with mining companies and regulatory bodies. Chile, as a major copper producer, has a large and safety-conscious mining workforce, making it an ideal testing ground for new safety technologies.
If successful, MindBio's platform could set a new standard for impairment testing in high-risk industries globally. The ability to detect impairment quickly and non-invasively could reduce workplace accidents, improve productivity, and lower liability costs for employers. Moreover, the technology could have applications beyond mining, including transportation, construction, and other sectors where safety is paramount.
For more information on MindBio Therapeutics and its technology, visit the company's newsroom at https://ibn.fm/MBQIF.
